Seres Therapeutics, Inc. (MCRB)
After hours:
| Previous Close | 1.0400 |
| Open | 1.0200 |
| Bid | 1.0300 x 1800 |
| Ask | 1.0500 x 4000 |
| Day's Range | 0.9800 - 1.0900 |
| 52 Week Range | 0.9100 - 7.1700 |
| Volume | |
| Avg. Volume | 3,584,157 |
| Market Cap | 138.305M |
| Beta (5Y Monthly) | 2.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1100 |
| Earnings Date | Nov 02, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.25 |
- Business Wire
Seres Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023; Webcast at 3:30 p.m. ET
CAMBRIDGE, Mass., November 28, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will participate at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023, at 3:30 p.m. ET.
PR NewswireFlagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics
Flagship Pioneering, the bioplatform innovation company, today unveiled Quotient Therapeutics, a company pioneering somatic genomics, the study of genetic variation at the cellular level, to discover therapeutics informed by new links between genes and disease. Flagship has made an initial commitment of $50 million to advance development of the company's platform following two years of development at Flagship Labs and pursue a pipeline of medicines across a wide range of therapeutic areas and mo
Insider MonkeySeres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2023 Earnings Call Transcript
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2023 Earnings Call Transcript November 4, 2023 Operator: Welcome to the Seres Therapeutics Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Kevin Mannix, Head of Investor Relations. Please go ahead. Kevin Mannix: […]
